Drug General Information
Drug ID
D08EEU
Former ID
DIB016258
Drug Name
Englitazone sodium
Synonyms
Englitazone sodium < Rec INNM; CP-68722 (racemate); CP-72467-02; CP-72467-2; (-)-5-[2(R)-Benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl]thiazolidine-2,4-dione sodium salt
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [526541]
Structure
Download
2D MOL

3D MOL

Formula
C20H18NNaO3S
Canonical SMILES
O=C1NC(=O)C(Cc2ccc3OC(Cc4ccccc4)CCc3c2)S1
InChI
1S/C20H19NO3S/c22-19-18(25-20(23)21-19)12-14-6-9-17-15(10-14)7-8-16(24-17)11-13-4-2-1-3-5-13/h1-6,9-10,16,18H,7-8,11-12H2,(H,21,22,23)
InChIKey
MVDXXGIBARMXSA-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Peroxisome proliferator activated receptor gamma Target Info Agonist [526541], [551871]
KEGG Pathway PPAR signaling pathway
AMPK signaling pathway
Osteoclast differentiation
Huntington's disease
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancer
NetPath Pathway IL1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway CCKR signaling map ST
Pathway Interaction Database Noncanonical Wnt signaling pathway
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Signaling events mediated by HDAC Class I
RXR and RAR heterodimerization with other nuclear receptor
Regulation of retinoblastoma protein
Reactome PPARA activates gene expression
Transcriptional regulation of white adipocyte differentiation
Nuclear Receptor transcription pathway
WikiPathways Wnt Signaling Pathway Netpath
Nuclear Receptors in Lipid Metabolism and Toxicity
Differentiation of white and brown adipocyte
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Transcriptional Regulation of White Adipocyte Differentiation
Adipogenesis
SREBP signalling
Nuclear Receptors
References
Ref 526541PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61.
Ref 526541PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.